Silymarin treatment of alcoholic liver disease
Orvosi Hetilap 131(29): 1607-1609
1990
ISSN/ISBN: 0030-6002 PMID: 2392321 Accession: 041367013
Full-Text Article emailed within 1 workday
Payments are secure & encrypted
References
Deak, G.; Muzes, G.; Lang, I.; Niederland, V.; Kristof, N.; Gonzalez Cabello, R.; Gergely, P.; Feher, J. 1990: Immunomodulatory effects of silymarin treatment in chronic alcoholic liver disease Orvosi Hetilap 131(24): 1291-1292, 1295-1296Salvagnini, M.; Martines, D.; Piccoli, A.; Sciarrone, R.; Rizzo, A.; Campesato, A.; Cielo, R.; Zambelli, V.; Zotti, S.; Naccarato, R. 1985: Silymarin treatment in alcoholic liver disease a double blind randomized clinical trial Journal of Hepatology (Suppl 1): S124
Hajiaghamohammadi, A.A.; Ziaee, A.; Oveisi, S.; Masroor, H. 2012: Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study Hepatitis Monthly 12(8): E6099
Bechynska, K.; Kosek, V.; Fenclova, M.; Muchova, L.; Smid, V.; Suk, J.; Chalupsky, K.; Sticova, E.; Hurkova, K.; Hajslova, J.; Vitek, L.; Stranska, M. 2021: The Effect of Mycotoxins and Silymarin on Liver Lipidome of Mice with Non-Alcoholic Fatty Liver Disease Biomolecules 11(11)
Berger, J.; Kowdley, K.V. 2003: Is silymarin hepatoprotective in alcoholic liver disease? Journal of Clinical Gastroenterology 37(4): 278-279
Cacciapuoti, F.; Scognamiglio, A.; Palumbo, R.; Forte, R.; Cacciapuoti, F. 2013: Silymarin in non alcoholic fatty liver disease World Journal of Hepatology 5(3): 109-113
Bunout, D.; Hirsch, S.; Petermann, M.; de la Maza, M.P.; Silva, G.; Kelly, M.; Ugarte, G.; Iturriaga, H. 1992: Controlled study of the effect of silymarin on alcoholic liver disease Revista Medica de Chile 120(12): 1370-1375
Colica, C.; Boccuto, L.; Abenavoli, L. 2017: Silymarin: An option to treat non-alcoholic fatty liver disease World Journal of Gastroenterology 23(47): 8437-8438
Abenavoli, L. 2011: Role of silymarin to treat fibrosis development in non-alcoholic fatty liver disease Hepatology Research: the Official Journal of the Japan Society of Hepatology 41(7): 668
Abenavoli, L.; Milic, N.; Capasso, F. 2012: Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin Endocrine 42(3): 754-755
Stephen Robert, J.M.; Peddha, M.S.; Srivastava, A.K. 2021: Effect of Silymarin and Quercetin in a Miniaturized Scaffold in Wistar Rats against Non-alcoholic Fatty Liver Disease Acs Omega 6(32): 20735-20745
Carvalho, L.C.F.; Ferreira, F.áv.M.; Dias, B.V.; Azevedo, D.C.d.; de Souza, G.H.B.; Milagre, M.M.; de Lana, M.; Vieira, P.M.d.A.; Carneiro, C.áu.M.; Paula-Gomes, S.íl.d.; Cangussu, S.D.; Costa, D.C. 2022: Silymarin inhibits the lipogenic pathway and reduces worsening of non-alcoholic fatty liver disease (NAFLD) in mice Archives of Physiology and Biochemistry 2022: 1-15
Hashem, A.; Shastri, Y.; Al Otaibi, M.; Buchel, E.; Saleh, H.; Ahmad, R.; Ahmed, H.; Al Idris, F.; Ahmed, S.; Guda, M.; Gillessen, A. 2021: Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the use of Silymarin Gastroenterology Insights 12(2): 155-165
Aller, R.ío.; Laserna, C.; Rojo, M.Án.; Mora, N.; García Sánchez, C.ón.; Pina, M.ía.; Sigüenza, R.; Durà, M.; Primo, D.; Izaola, O.; de Luis, D. 2018: Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin e response in subjects with non-alcoholic fatty liver disease Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva 110(10): 634-640
Aller, R.; Izaola, O.; Gómez, S.; Tafur, C.; González, G.; Berroa, E.; Mora, N.; González, J.M.; de Luis, D.A. 2015: Effect of silymarin plus vitamin e in patients with non-alcoholic fatty liver disease. a randomized clinical pilot study European Review for Medical and Pharmacological Sciences 19(16): 3118-3124
Liang, W.; Chikritzhs, T.; Pascal, R.; Binns, C.W. 2011: Mortality rate of alcoholic liver disease and risk of hospitalization for alcoholic liver cirrhosis, alcoholic hepatitis and alcoholic liver failure in Australia between 1993 and 2005 Internal Medicine Journal 41(1a): 34-41
Hauksson, K.; Arnardottir, M.; Agustsson, A.S.; Magnusdottir, B.; Baldursdottir, M.; Lund, S.H.; Kalaitzakis, E.; Björnsson, E. 2018: Sa1082 - Relationship Between Per Capita Alcohol Consumption and the Incidence of Alcoholic Pancreatitis and Alcoholic Liver Disease. Comparison Between Pancreas Disease and Alcoholic Liver Disease Gastroenterology 154(6): S-234-S-235
Karim, G.; Bansal, M.B. 2023: Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis Touchreviews in Endocrinology 19(1): 60-70
Fehér, J.; Deák, G.; Müzes, G.; Láng, I.; Niederland, V.; Nékám, K.; Kárteszi, M. 1989: Liver-protective action of silymarin therapy in chronic alcoholic liver diseases Orvosi Hetilap 130(51): 2723-2727
De Avelar, C.R.; Nunes, B.V.C.; da Silva Sassaki, B.; Dos Santos Vasconcelos, M.; de Oliveira, L.P.M.ãe.; Lyra, A.é C.; Bueno, A.A.; de Jesus, R.ân.P. 2023: Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial Trials 24(1): 177